Aptose

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.

Royal Bank of Canada lowered their price target on shares of Aptose Biosciences from $6.00 to $5.00 and set an outperform rating for the company in a report on Wednesday, November 2nd.

Aptose Biosciences has a fifty-two week low of $1.15 and a fifty-two week high of $7.49.

On average, sell-side analysts forecast that Aptose Biosciences Inc. will post -0.59 earnings per share for the current fiscal year.

Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Me.

Piper Sandler assumed coverage on shares of Aptose Biosciences in a research note on Thursday, January 9th.

This analysis assumes further fundraising, and as the last few months have underscored, there is definitely risk to those fundraising assumptions as Aptose may have to raise more money at lower prices than I currently model.